{"disease":{"id":"carcinoma-of-the-head-and-neck","name":"carcinoma of the head and neck"},"drugs":{"marketed":[{"drug_id":"pf-06823859","indication_name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxyurea","indication_name":"Locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"pf-06940434","indication_name":"Squamous Cell Carcinoma of the Head and Neck","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06940434","generic_name":"pf-06940434","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2","quality_score":null,"revenue":null,"mechanism":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2"}],"offLabel":[],"totalMarketed":4,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT02551159","title":"Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":823,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02369874","title":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04459715","title":"A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":730,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT02952586","title":"Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":697,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04672772","title":"Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.","phase":"","overall_status":"COMPLETED","enrollment_count":531,"lead_sponsor_name":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","has_results":false},{"nct_id":"NCT05068609","title":"A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)","phase":"","overall_status":"COMPLETED","enrollment_count":509,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04050761","title":"A Study of Nivolumab in Patients With Head and Neck Cancer.","phase":"","overall_status":"COMPLETED","enrollment_count":502,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05931445","title":"Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Comprehensive Support Project for Oncology Research","has_results":false},{"nct_id":"NCT02543476","title":"SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)","phase":"","overall_status":"COMPLETED","enrollment_count":412,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03452137","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":406,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07361666","title":"Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","has_results":false},{"nct_id":"NCT03843671","title":"Hyperbaric Radiation Sensitization of Head and Neck Cancers","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"National Baromedical Services","has_results":false},{"nct_id":"NCT04590963","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":370,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02105636","title":"Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07320690","title":"De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":356,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT02499328","title":"Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03855384","title":"Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":334,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04787042","title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Simcha IL-18, Inc.","has_results":false},{"nct_id":"NCT05123950","title":"A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT05721755","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":290,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT03645928","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":245,"lead_sponsor_name":"Iovance Biotherapeutics, Inc.","has_results":false},{"nct_id":"NCT04517019","title":"Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":201,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT05815927","title":"Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT02001623","title":"Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT05075980","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05329532","title":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"Scancell Ltd","has_results":false},{"nct_id":"NCT04609566","title":"Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05918510","title":"Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus","phase":"","overall_status":"RECRUITING","enrollment_count":142,"lead_sponsor_name":"Regina Elena Cancer Institute","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02499120","title":"Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03330249","title":"Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Groupe Oncologie Radiotherapie Tete et Cou","has_results":false},{"nct_id":"NCT05651022","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Indaptus Therapeutics, Inc","has_results":false},{"nct_id":"NCT04597476","title":"A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":119,"lead_sponsor_name":"Hi-Q Marine Biotech International, Ltd.","has_results":false},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03454451","title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Corvus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07507578","title":"A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":114,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT02207530","title":"Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03723967","title":"FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT02841748","title":"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT03491176","title":"Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03139058","title":"Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT02573493","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT01332266","title":"E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT03370276","title":"Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04152018","title":"Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Pfizer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}